Direct-to-Consumer Advertising of Pharmaceuticals as a Matter of Corporate Social Responsibility?
Direct-to-consumer advertising (DTCA) of prescription drugs has been a heavily contested issue over the past decade, touching on several issues of responsibility facing the pharmaceutical industry. Much research has been conducted on DTCA, but hardly any studies have discussed this topic from a corp...
| Authors: | ; |
|---|---|
| 格式: | 電子 Article |
| 語言: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | 載入...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| 出版: |
Springer Science + Business Media B. V
2010
|
| In: |
Journal of business ethics
Year: 2010, 卷: 94, 發布: 2, Pages: 211-224 |
| Further subjects: | B
direct-to-consumer-advertising (DTCA)
B consumer safety B Pharmaceutical Industry B Corporate social responsibility (CSR) |
| 在線閱讀: |
Presumably Free Access Volltext (JSTOR) Volltext (lizenzpflichtig) |
| 總結: | Direct-to-consumer advertising (DTCA) of prescription drugs has been a heavily contested issue over the past decade, touching on several issues of responsibility facing the pharmaceutical industry. Much research has been conducted on DTCA, but hardly any studies have discussed this topic from a corporate social responsibility (CSR) perspective. In this article, we use several elements of CSR, emphasising consumer autonomy and safety, to analyse differences in DTCA practices within two different policy contexts, the United States of America and the European Union (EU). Doing so results in an alternative analysis of the struggle between proponents and opponents of DTCA from a CSR perspective, adding an alternative view on this debate. |
|---|---|
| ISSN: | 1573-0697 |
| Contains: | Enthalten in: Journal of business ethics
|
| Persistent identifiers: | DOI: 10.1007/s10551-009-0257-z |